Mei Ri Jing Ji Xin Wen·2025-04-08 15:13Core Insights - The human rabies vaccine market in China is saturated with 13 manufacturers having approved products, with Vero cell vaccines accounting for approximately 90% of the market share [1][3] - Fosun Pharma launched a lyophilized human rabies vaccine, indicating a product upgrade from its previous liquid formulation, aiming to enhance market competitiveness [1][2] - The company believes there is significant growth potential in the rabies vaccine market, as current vaccination rates among exposed individuals are below one-third, despite 100-200 annual deaths from rabies in China [1][3] Company Developments - Fosun Pharma's lyophilized rabies vaccine utilizes the CTN-1 strain and is the first in China to implement serum-free virus culture technology on a large scale, improving cell culture efficiency and vaccine efficacy [2] - The vaccine has received registration approval in March 2024 and offers two vaccination schedules, both validated through Phase III randomized controlled trials [2] - Phase III trial results showed a 76.06% seroconversion rate at 7 days for the 2-1-1 schedule, outperforming a comparable product's 47.81% rate, indicating faster immune response and reduced vaccination frequency [2] Industry Context - The rabies vaccine market is characterized by intense competition, with multiple manufacturers and various vaccine types available, including Vero cell, human diploid cell, and hamster kidney cell vaccines [3] - Despite the competitive landscape, the overall market space remains large, and there is a call for increased public awareness and vaccination rates to expand the market [3] - Fosun Pharma is also exploring international markets, particularly in the Middle East, Southeast Asia, and South America, while emphasizing the need to improve domestic vaccination rates as a priority [4]